4-<(S)-1-phenylethylamino>cyclohexan-1-one ethylene acetal | 247208-98-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-<(S)-1-phenylethylamino>cyclohexan-1-one ethylene acetal
• 英文别名: ((1S)-1-phenylethyl)(1,4-dioxaspiro[4.5]dec-8-yl)amine；N-[(1S)-1-phenylethyl]-1,4-dioxaspiro[4.5]decan-8-amine
• CAS: 247208-98-6
• 化学式: C₁₆H₂₃NO₂
• 分子量: 261.364
• InChiKey: RLDOTEXAQXQZQL-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-<(S)-1-phenylethylamino>cyclohexan-1-one ethylene acetal 在 盐酸 、 三乙胺 、 六甲基二硅氮烷 作用下， 以 四氢呋喃 、 二氯甲烷 、 正戊烷 为溶剂， 反应 36.0h， 生成 2,2,2-trichloro-N-<(S)-1-phenylethyl>-N-(4-trimethylsilyloxycyclohex-3-en-1-yl)acetamide
  参考文献：
  名称：

  通过自由基闭环合成对映体纯的2-氮杂双环[3.3.1]壬烷

  摘要：

  描述了通过带有（S）-N -1-苯基乙基取代基的三氯乙酰胺基与化合物7中的甲硅烷基烯醇醚部分的分子内自由基反应的对映体纯的2-氮杂双环[3.3.1]壬烷的第一次合成。该方法允许分别制备2-氮杂双环[3.3.1]壬烷-3,6-二酮3和ent - 3的两个对映体。在环化步骤中，通过初始的自由基易位过程，β-内酰胺8和诺啡烷9也由7形成。

  DOI：

  10.1016/s0957-4166(99)00221-9
• 作为产物：
  描述：

  1,4-环己二酮单乙二醇缩酮 在 sodium tetrahydroborate 、 4 A molecular sieve 作用下， 以 甲醇 为溶剂， 反应 8.0h， 生成 4-<(S)-1-phenylethylamino>cyclohexan-1-one ethylene acetal
  参考文献：
  名称：

  通过自由基闭环合成对映体纯的2-氮杂双环[3.3.1]壬烷

  摘要：

  描述了通过带有（S）-N -1-苯基乙基取代基的三氯乙酰胺基与化合物7中的甲硅烷基烯醇醚部分的分子内自由基反应的对映体纯的2-氮杂双环[3.3.1]壬烷的第一次合成。该方法允许分别制备2-氮杂双环[3.3.1]壬烷-3,6-二酮3和ent - 3的两个对映体。在环化步骤中，通过初始的自由基易位过程，β-内酰胺8和诺啡烷9也由7形成。

  DOI：

  10.1016/s0957-4166(99)00221-9

文献信息

• Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
  申请人：Albers J. Ronald

  公开号：US20060287344A1

  公开（公告）日：2006-12-21

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供的是具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，以及包含有效量氨基嘌呤化合物的组合物和用于治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合征、与疾病相关的消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Albers Ronald J.

  公开号：US20090275564A1

  公开（公告）日：2009-11-05

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量氨基嘌呤化合物的组合物，以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、与疾病相关的消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK途径治疗或预防的疾病的方法，包括向需要治疗的患者注射有效量的氨基嘌呤化合物。
• Methods of treatment and prevention using haloaryl substituted aminopurines
  申请人：Bennett L. Brydon

  公开号：US20080021048A1

  公开（公告）日：2008-01-24

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量的氨基嘌呤化合物的组合物以及用于治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或通过抑制JNK通路可治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF
  申请人：Albers Ronald J.

  公开号：US20090312320A1

  公开（公告）日：2009-12-17

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包含有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要的患者施用有效量的氨基嘌呤化合物。
• METHODS OF MODULATING INFLAMMATORY CELL RECRUITMENT AND GENE EXPRESSION USING HALOARYL SUBSTITUTED AMINOPURINES
  申请人：Bennett Brydon L.

  公开号：US20100249066A1

  公开（公告）日：2010-09-30

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包括有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合征、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK途径治疗或预防的疾病的方法，包括向需要治疗的患者中施用有效量的氨基嘌呤化合物。